Rana McKay, MD, says that given the frontline shift from anti-VEGF monotherapy to immunotherapy doublets for advanced renal cell carcinoma, many of the studies informing the second-line setting have become “somewhat antiquated.”
Rana McKay, MD, discusses the evolving treatment paradigm in the second-line setting for advanced renal cell carcinoma now that immunotherapy has revolutionized the first-line approach. McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology
January 19th 2023“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
2 Clarke Drive
Cranbury, NJ 08512